|
Volumn 260, Issue 2, 2000, Pages 334-339
|
F9 Embryonal carcinoma cells engineered for tamoxifen-dependent Cre-mediated site-directed mutagenesis and doxycycline-inducible gene expression
a a a |
Author keywords
F9 embryonal carcinoma cells; Inducible gene expression; Ligand inducible Cre recombinase; loxP sites; Mutagenesis; Retinoid; Tamoxifen; Tet system; Tetracycline
|
Indexed keywords
DOXYCYCLINE;
GENE PRODUCT;
PROTEIN LOXP;
PROTEIN RTTA;
RECOMBINASE;
TAMOXIFEN;
TETRACYCLINE;
TRANSACTIVATOR PROTEIN;
UNCLASSIFIED DRUG;
ANIMAL CELL;
ARTICLE;
CANCER CELL;
CONTROLLED STUDY;
EMBRYO;
EMBRYONAL CARCINOMA;
GENE CONTROL;
GENE EXPRESSION REGULATION;
GENE FUNCTION;
GENE INACTIVATION;
GENETIC ENGINEERING;
MAMMAL CELL;
MOUSE;
NONHUMAN;
PRIORITY JOURNAL;
REPORTER GENE;
REPRESSOR GENE;
SITE DIRECTED MUTAGENESIS;
|
EID: 0034331337
PISSN: 00144827
EISSN: None
Source Type: Journal
DOI: 10.1006/excr.2000.5022 Document Type: Article |
Times cited : (17)
|
References (35)
|